Wednesday, 22 September, 2021
Home Tags Zydus Cadila

Topic: Zydus Cadila

The ZyCov-D vaccine |

ZyCov-D price talks still on, but India begins training for use of needle-free applicator

First instalment of ZyCov-D, a three-dose Covid vaccine manufactured by Zydus Cadila, is expected next month. Vaccine doesn't require a needle injection to be administered.
Screenshot of virtual presser by Dr Sharvil Patel, MD, Zydus Group, on 21 August 2021 | ANI

Zycov D is 66% effective against Delta variant of SARS-Cov-2, claims Zydus Cadila

Zydus' claim comes a day after it being given emergency use authorisation in India, and is the only vaccine approved for use in 12-18 years age group.
Zydus Cadila has developed the DNA plasmid-based Covid vaccine ZyCoVD | Marco Verch | Flickr

Three-dose ZyCoV-D vaccine could be just two doses, says pharma firm Zydus Cadila

Zydus Cadilla says its test data shows that the vaccine appears to be just as effective in 2 doses as 3, and will be administered 28 days apart.
Covid vaccine ZyCoV-D is being developed by Gujarat-based Zydus Cadila | Photo:

Zydus Cadila applies for approval to ZyCov-D, India’s 1st Covid vaccine tested on 12-18-yr-olds

If ZyCov-D gets the approval, it will be the fifth vaccine authorised for use in India after Covishield, Covaxin, Sputnik V and Moderna.
Covid vaccine ZyCoV-D is being developed by Gujarat-based Zydus Cadila | Photo:

India’s ZyCoV-D set to become world’s first DNA Covid vaccine as govt approval likely soon

Gujarat-based Zydus Cadila has told Modi govt that it could apply for emergency use authorisation for ZyCoV-D vaccine in the next 10-12 days.
A doctor checks CT Scan of a Covid patient in Greater Noida (file photo) | PTI Photo

Zydus Cadila gets nod for clinical trials of monoclonal antibodies cocktail to treat Covid

Zydus said that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild Covid.

Zydus’s antiviral drug Virafin gets emergency approval to treat moderate Covid patients

In statement, Zydus Cadila says phase 3 clinical trial data showed Virafin reduced oxygen requirement in patients, & and that a significant number of them tested negative by 7th day.

Indian pharma firms Zydus, Alembic recall 2 drugs in US over ‘life-threatening’ consequences

Zydus Cadila recalls injection for treatment of herpes infections over complaints of crystallisation in vials, Alembic Pharmaceuticals recalls its high BP drug due to labelling error.

Off The Cuff with Dr Randeep Guleria

Randeep Guleria, Director, All India Institute of Medical Sciences, New Delhi, was the guest at this edition of ThePrint's Off the Cuff. In a conversation with Editor-in-Chief Shekhar Gupta, Guleria said India’s vaccination drive will expand to include younger people as soon as India has enough vaccines available. It might happen soon as the vaccine makers are ramping up the production capacities, he said. Also, the government may look at approving other vaccines, including Russia’s Sputnik V and Zydus Cadila’s vaccine, Guleria said. He counted the lessons that Covid-19 has made India learn — it includes the importance of strong research and development in medical science that eventually led India to develop its own Covid vaccine. The eminent pulmonologist said the clinicians started off with knowing nothing about Covid-19 and thought it was like viral pneumonia. With time, clinicians learnt that Covid is predominantly viral pneumonia that causes severe lung infection but...

On Camera


Sony India signs deal to buy Zee Entertainment, will own 53% of merged entity

Move came after Zee shareholders sought removal of key officials. However, Zee CEO Punit Goenka, whose removal was sought, will lead the merged entity.


Air Marshal VR Chaudhari | Twitter/@PIB_India

Air Marshal VR Chaudhari appointed as next Chief of Air Staff

Air Marshal Chaudhari, presently serving as Vice Chief of the Air Staff, will take charge after the retirement of Air Chief Marshal Bhadauria on 30 Sept, the defence ministry said.

Modi at 71 has zero challenge. But one CM is emulating him, a divisive, rising BJP star

Yogi has put high command in a tough situation. If he doesn’t win UP next year, it will set back BJP’s prospects in 2024. If he wins, it will be seen as his win as much as theirs.